请使用支持JavaScript的浏览器! Medchemexpress/Vancomycin hydrochloride/HY-17362/10mM*1mL in DMSO_蚂蚁淘,【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城
商品信息
联系客服
Medchemexpress/Vancomycin hydrochloride/HY-17362/10mM*1mL in DMSO
郑重提醒:
无质量问题不接受退换货,下单前请仔细核对信息。
下单后请及时联系客服核对商品价格,订单生效后再付款。
Medchemexpress/Vancomycin hydrochloride/HY-17362/10mM*1mL in DMSO
美元价:
(友情提示:该价格仅为参考,欢迎联系客服询价!)
数    量:
免费咨询热线
4000-520-616
Vancomycinhydrochlorideisanantibioticforthetreatmentofbacterialinfections.
Description

Vancomycinhydrochlorideisanantibioticforthetreatmentofbacterialinfections.

InVitro

Vancomycinisalargeglycopeptidecompoundwithamolecularweightof1450Da[1].Vancomycinisauniqueglycopeptidestructurallyunrelatedtoanycurrentlyavailableantibiotic.ItalsohasauniquemodeofactioninhibitingthesecondstageofcellwallsynthesisofsusceptIBLebacteria.VancomycinisactiveagainstalargenumberofspeciesofGram-positivebacteria,suchasStaphylococcusaureus,Staph.epidermidis,Str.agalactiae,Str.bovis,Str.mutans,viridansstreptococci,enterococci[2].

InVivo

VancomycinisadmiNISTeredintravenously,withastandardinfusiontimeofatleast1h,tominimizeinfusion-relatedadverseeffects.Subjectswithnormalcreatinineclearance,vancomycinhasanα-distributionphaseof30minto1handaβ-eliminationhalf-lifeof6-12h.Thevolumeofdistributionis0.4–1L/kg.Thebindingofvancomycintoproteinrangesfrom10%to50%.Factorsthataffecttheoverallactivityofvancomycinincludeitstissuedistribution,inoculumsize,andprotein-bindingeffects[1].Vancomycintreatmentofinfectedmiceisassociatedwithimprovedclinical,diarrhea,andhistopathologyscoresandsurvivalduringtreatment[3].

References
  • [1].RybakMJ,etal.Thepharmacokineticandpharmacodynamicpropertiesofvancomycin.ClinInfectDis.2006Jan1;42Suppl1:S35-9.

    [2].WatanakunakornC,etal.Modeofactionandin-vitroactivityofvancomycin.JAntimicrobChemother.1984Dec;14SupplD:7-18.

    [3].WarrenCA,etal.Vancomycintreatment"sassociationwithdelayedintestinaltissueinjury,clostridialovergrowth,andrecurrenceofClostridiumdifficileinfectioninmice.AntimicrobAgentsChemother.2013Feb;57(2):689-96.

PreparingStockSolutions
ConcentrationVolumeMass1mg5mg10mg
1mM0.6731mL3.3654mL6.7307mL
5mM0.1346mL0.6731mL1.3461mL
10mM0.0673mL0.3365mL0.6731mL
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent.
AnimalAdministration
[3]

Mouse:Onesetofexperimentsisperformedinwhichinfectedmicearetreatedwithvancomycin(50mg/kg)dailyfor1,2,3,or5daysandareobservedfor21dayspostinfectionorwithvancomycin(20mg/kg)dailyforeither5or10daysandmonitoringfor15dayspostinfection[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

References
  • [1].RybakMJ,etal.Thepharmacokineticandpharmacodynamicpropertiesofvancomycin.ClinInfectDis.2006Jan1;42Suppl1:S35-9.

    [2].WatanakunakornC,etal.Modeofactionandin-vitroactivityofvancomycin.JAntimicrobChemother.1984Dec;14SupplD:7-18.

    [3].WarrenCA,etal.Vancomycintreatment"sassociationwithdelayedintestinaltissueinjury,clostridialovergrowth,andrecurrenceofClostridiumdifficileinfectioninmice.AntimicrobAgentsChemother.2013Feb;57(2):689-96.

MolecularWeight

1485.72

Formula

C₆₆H₇₆Cl₃N₉O₂₄

CASNo.

1404-93-9

Storage
Powder-20°C3years
 4°C2years
Insolvent-80°C6months
 -20°C1month
Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

DMSO:24mg/mL

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:>98.0%